Overview

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Status:
Completed

Trial end date:
2018-09-14

Target enrollment:

Participant gender:

Summary

This is a Phase 2, multi-center, open-label study to evaluate the efficacy, safety and pharmacokinetics of quizartinib monotherapy in Japanese subjects with FLT3-ITD positive refractory or relapsed acute myeloid leukemia.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo Co., Ltd.

Collaborators:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.